Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Anika Therapeutics (NASDAQ: ANIK) announced that on April 1, 2026 it granted restricted stock units covering an aggregate of 3,138 shares to one newly hired non-executive employee as an inducement under Nasdaq Listing Rule 5635(c)(4).

The RSUs were approved under the Anika Therapeutics 2021 Inducement Plan by the compensation committee, do not require stockholder approval, and vest in three equal annual installments subject to continued service and the equity award agreement terms.

News Market Reaction – ANIK

-0.34%

-0.34% News Effect

On the day this news was published, ANIK declined 0.34%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a routine equity inducement: 3,138 RSUs granted under the 2021 Inducement ...

Analysis

This announcement details a routine equity inducement: 3,138 RSUs granted under the 2021 Inducement Plan to a new non-executive employee, vesting over three years under Nasdaq Listing Rule 5635(c)(4). It follows a series of recent equity compensation filings for executives and directors, underscoring Anika’s use of stock-based awards for alignment and retention. Investors may monitor future grants, plan usage, and broader compensation trends alongside core drivers such as earnings, guidance, and regulatory milestones.

Key Figures

RSU grant size: 3,138 shares Vesting schedule: 3 installments

2 metrics

RSU grant size 3,138 shares Aggregate restricted stock units for one new non-executive employee

Vesting schedule 3 installments RSUs vest in three equal annual tranches from April 1, 2026 grant

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 26	Earnings results	Positive	+16.9%	Reported Q4 and FY 2025 results with margin expansion and 2026 guidance.
Feb 18	Conference appearance	Positive	+1.7%	Announced CEO presentation and investor meetings at a musculoskeletal conference.
Feb 12	Earnings preview	Neutral	+1.5%	Scheduled release date and call details for Q4 and year-end 2025 results.
Feb 04	Board appointment	Positive	+6.5%	Lumicell added Anika’s Executive Chair to its board, highlighting her experience.
Jan 08	Leadership transition	Neutral	-3.0%	Announced CEO change, new Executive Chair, lead director, and reaffirmed 2025 guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent ANIK news—earnings, conferences, and leadership updates—has generally seen positive next-day reactions, except for one leadership transition headline that coincided with a decline.

Recent Company History

Over the past few months, Anika has focused on financial execution and leadership evolution. Q4 and FY 2025 results on Feb 26 highlighted $30.6M quarterly and $112.8M full‑year revenue, margin expansion, and 2026 guidance, with a strong positive price reaction. Management visibility was reinforced through conference participation and a leadership transition effective Feb 1, 2026. Today’s RSU inducement grant fits into a pattern of using equity compensation, alongside prior insider awards in March filings, to support management and employee alignment.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), equity award agreement

4 terms

restricted stock units financial

"Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,138 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"The RSUs will vest in three equal installments on each of the first three anniversaries"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity award agreement financial

"The RSUs are subject to the terms and conditions of the equity award agreement"

A written contract that grants someone ownership rights or the option to buy company shares under specific conditions, such as earning the shares over time or meeting performance targets. Investors care because these agreements affect how many shares may be issued in the future (dilution), how company leaders are motivated and kept long-term, and the company’s reported expenses—think of it like a promised ownership bonus that vests like a job-based reward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on April 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,138 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

The RSUs will vest in three equal installments on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.

The RSUs are subject to the terms and conditions of the equity award agreement approved by Anika. The RSUs were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.

About Anika

Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com

FAQ

What did Anika (ANIK) announce on April 3, 2026 about inducement RSUs?

Anika granted RSUs covering 3,138 shares to one newly hired non-executive employee on April 1, 2026. According to Anika, the award was made under the 2021 Inducement Plan as a Nasdaq Listing Rule 5635(c)(4) inducement and approved by the compensation committee.

How do the ANIK inducement RSUs vest and when are vesting dates?

The RSUs vest in three equal installments on each of the first three anniversaries of the April 1, 2026 grant date. According to Anika, each installment vests only if the grantee provides continuous service through the relevant vesting date.

Was Anika's April 2026 RSU grant subject to stockholder approval (ANIK)?

No, the RSUs were granted under the Anika Therapeutics 2021 Inducement Plan and were not subject to stockholder approval. According to Anika, the compensation committee approved the inducement pursuant to delegated authority.

Why did Anika use a Nasdaq 5635(c)(4) inducement grant for the new hire (ANIK)?

Anika used the Nasdaq Rule 5635(c)(4) inducement to make the RSU award a material part of hiring compensation for the new employee. According to Anika, this rule permits grants made as an inducement to accept employment without prior shareholder approval.

How many shares were involved in Anika's inducement grant and who received them (ANIK)?

The inducement grant covered an aggregate of 3,138 shares of common stock to one newly hired non-executive employee. According to Anika, the award was granted April 1, 2026 under the amended 2021 Inducement Plan.